SGLT-2 Inhibitors Tied to Lower Risk for Autoimmune Rheumatic Diseases in Adults With T2D
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.
According to a study, SGLT-2 inhibitors are associated with a reduced risk for autoimmune rheumatic diseases compared with sulfonylureas among adults with type 2 diabetes.
- Researchers examined use of SGLT-2 inhibitors and the risk for autoimmune rheumatic diseases in a retrospective cohort study.
- The study involved 2,032,157 adults with type 2 diabetes from a nationwide health care database in South Korea.
- After propensity score weighting, the analysis included 1,030,088 SGLT-2 inhibitor initiators and 1,002,069 sulfonylurea initiators.
The researchers found that the weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.
No direct quote available in the given text.
Author's summary: SGLT-2 inhibitors reduce autoimmune disease risk in T2D adults.
More News
- Jenna Ortega says AI 'has no soul' and warns it has no place in filmmaking
- Nashville Predators Official Instagram Profile Overview
- Jenna Ortega at Marrakech Film Festival
- Russia Berates Israel Over Gaza At UN
- UFC Walkouts: When Fighters Turn Pressure Into Energy
- Mimi Mefo, Nzui Manto, Paul Chouta, Boris Bertolt, Bernard ...
- A PLOT TO DESTABILIZE CAMEROON? (REVELATIONS)
- THE BEST MMA WALKOUT EVER @wingedc
- Jenna Ortega opens up about AI’s role and emotional void in modern filmmaking
- L'Express | Paris : visite de Zelensky annoncée